Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Burke on Ongoing Investigations in Lymphoma Treatment

June 11th 2024

John M. Burke, MD discussed ongoing investigations into the treatment of lymphoma that were presented at ASCO 2024.

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

June 11th 2024

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.

CDK9 Inhibitor SLS009 Displays Activity in Relapsed/Refractory AML

June 10th 2024

Enrollment of patients in a phase 2 study evaluating SLS009 in relapsed/refractory AML has been completed and the agent demonstrated initial efficacy.

SL-172154 Receives FDA Orphan Drug Designation in AML

June 10th 2024

SL-172154 has been granted orphan drug designation from the FDA in acute myeloid leukemia.

Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML

June 7th 2024

Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.

Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML

June 6th 2024

Eunice S. Wang, MD, discusses current unmet needs and efforts to move menin inhibitors into earlier lines of therapy in relapsed/refractory AML.

UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe

June 5th 2024

The European Commission granted orphan drug designation to UCART22 for acute lymphoblastic leukemia.

OS Data Could Dictate Next Directions for Uproleselan in R/R AML

June 4th 2024

A clinically meaningful but not statistically significant improvement in OS was observed with uproleselan plus chemotherapy vs chemotherapy alone in primary refractory AML.

Decreased Azacitadine Dosing Shows Consistent Safety in Lower- and Intermediate-Risk MDS

June 3rd 2024

Treatment with a decreased dosing schedule of oral azacitidine was consistent with what has been previously known about the agent in intermediate-risk myelodysplastic syndrome.

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

June 2nd 2024

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma

June 1st 2024

Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.

Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur

June 1st 2024

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations

June 1st 2024

Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

May 31st 2024

Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

May 30th 2024

Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.

Vanderbilt Symposium Highlights Recent Data on Novel Agents Under Evaluation in Hematologic Malignancies

May 24th 2024

Katie S. Gatwood, PharmD, BCOP, explains next steps with novel agents in the hematologic oncology field that have the potential to change practice.

Dr Kitko on the Utility of Obe-Cel in Pediatric Patients With B-ALL

May 23rd 2024

Carrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Leslie on the Utility of Axi-cel in High-Risk LBCL

May 22nd 2024

Lori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.

Eckfeldt Looks Towards the Future of AML and MDS Care

May 22nd 2024

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

May 22nd 2024

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.